OmniAb, Inc. a biotechnology company based in Emeryville, California, has recently made significant breakthroughs in the field of antibody engineering. Through the publication of a scientific paper in the Journal of Immunology, the company has demonstrated that chickens can be genetically modified to produce functional heavy chain-only single-domain antibodies (sdAbs). This innovation has the potential to revolutionize the production of antibodies, as sdAbs are known for their small size, robustness, and modular properties. Additionally, at the 20th Annual PEGS Boston Summit, OmniAb presented xPloration, a high-throughput single B-cell screening platform that utilizes machine learning and artificial intelligence (AI) to enhance antibody discovery.
Chickens as Producers of Heavy Chain-Only Single-Domain Antibodies
In the published paper, OmniAb describes how chickens have been genetically engineered with a truncated light chain transgene, enabling the production of heavy chain-only single-domain antibodies. Conventionally, sdAbs are naturally found in camelids, such as llamas and camels. These antibodies consist of a single heavy chain domain, making them smaller and more stable compared to conventional antibodies. By successfully introducing the genetic modification in chickens, OmniAb has expanded the potential sources for sdAbs production, leading to a more cost-effective and scalable antibody generation process.
The Use of xPloration in Antibody Discovery
OmniAb’s participation at the 20th Annual PEGS Boston Summit showcased its innovative screening platform, xPloration. This high-throughput single B-cell screening platform integrates machine learning and AI techniques to accelerate the process of bispecific antibody discovery. Through the analysis of large datasets, xPloration aims to identify promising antibody candidates with enhanced specificity and efficacy. The use of machine learning and AI provides a more efficient and targeted approach, minimizing the time and resources required in the antibody development process.
Implications and Future Prospects
The ability to genetically engineer chickens to produce heavy chain-only single-domain antibodies presents numerous opportunities in the field of antibody engineering. These antibodies have proven to be versatile and adaptable building blocks with a wide range of applications, including diagnostics, therapeutics, and research tools. Furthermore, OmniAb’s xPloration platform demonstrates the integration of cutting-edge technologies to streamline the antibody discovery process, expediting the development of new drug candidates.
Comments